reports
Cogent Biosciences Inc: 1 director
A director at Cogent Biosciences Inc sold 3,500,000 shares at 36.400USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Moody's Ratings downgraded Superior Industries' CFR to Caa3; outlook t...
Moody's Ratings (Moody's) downgraded Superior Industries International, Inc.'s (Superior) corporate family rating (CFR) to Caa3 from B3 and the probability of default rating to Caa3-PD from B3-PD. We also downgraded the company's priority senior secured revolving credit facility rating to B2 from B...
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 W...
Moody's Ratings affirms Superior Industries' B3 corporate family ratin...
Moody's Ratings (Moody's) affirmed Superior Industries International, Inc.'s (Superior) corporate family rating at B3, the probability of default rating at B3-PD and the company's priority senior secured revolving credit facility rating at Ba3. At the same time, we assigned a B3 rating to the new se...
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to...
Moody's Ratings downgrades Superior Industries' CFR to B3, senior secu...
Moody's Ratings (Moody's) downgraded Superior Industries International, Inc.'s (Superior) corporate family rating (CFR) to B3 from B2 and the probability of default rating to B3-PD from B2-PD. Moody's also downgraded the ratings on the company's priority senior secured revolving credit facility to B...
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to l...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) ...
CapStar Financial Holdings, Inc. Announces Quarterly Dividend of $0.11...
CapStar Financial Holdings, Inc. Announces Quarterly Dividend of $0.11 per Share NASHVILLE, Tenn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ: CSTR) announced that on January 26, 2024, the Board of Directors of the Company approved a quarterly dividend of $0.11 per common share payable on February 21, 2024 to shareholders of record of CapStar’s common stock as of the close of business on February 7, 2024. About CapStar Financial Holdings, Inc. CapStar Financial Holdings, Inc. is a bank holding company headquartered in Nashville, Tennessee and o...
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operati...
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in presentations at the American Society of Nephrology (ASN) K...
- Dave Nicoski
- Ross LaDuke
WABC WESTAMERICA BANCORPORATION
RGR STURM RUGER & COMPANY INC.
PPC PILGRIM'S PRIDE CORPORATION
MCY MERCURY GENERAL CORPORATION
LDOS LEIDOS HOLDINGS INC.
IBCP INDEPENDENT BANK CORP. MICHIGAN
HMN HORACE MANN EDUCATORS CORPORATION
HII HUNTINGTON INGALLS INDUSTRIES INC.
GILD GILEAD SCIENCES INC.
EAT BRINKER INTERNATIONAL INC.
CUBI CUSTOMERS BANCORP INC.
CRK COMSTOCK RESOURCES INC.
CL COLGATE-PALMOLIVE COMPANY
BPMC BLUEPRINT MEDICINES CORP.
AR ANTERO RESOURCES CORPORATION
SAFT SAFETY INSURANCE GROUP INC.
AROW ARROW FINANCIAL CORP.
CHE CHEMED CORPORATION
NOC NORTHROP GRUMMAN CORPORATION
LMT LOCKHEED MARTIN CORPORATION
THG HANOVER INSURANCE GROUP INC.
WRB W. R. BERKLEY CORPORATION
ACNB ACNB CORP.
SRCE 1ST SOURCE CORP.
CSTR CAPSTAR FINANCIAL HOLDINGS
BL BEST LEASE
WRK WESTROCK COMPANY
NKE NIKE INC. CLASS B
ESSA ESSA BANCORP
CHMG CHEMUNG FINANCIAL CORP.
SRRK SCHOLAR ROCK HOLDING CORPORATION
ALXO ALX ONCOLOGY HOLDINGS
MODV MODIVCARE INC
VSCO VICTORIA'S SECRET & CO
CHK CHESAPEAKE ENERGY CORP
FRST PRIMIS FINANCIAL CORP
P RAILPOWER TECHNOLOGIES CORP.
MSBI HAMASHBIR 365 LTD
CapStar Reports Third Quarter 2023 Results
CapStar Reports Third Quarter 2023 Results NASHVILLE, Tenn., Oct. 26, 2023 (GLOBE NEWSWIRE) -- CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ:CSTR) today reported net income of $8.9 million or $0.43 per diluted share, for the quarter ended September 30, 2023, compared with net income of $7.8 million or $0.37 per diluted share, for the quarter ended June 30, 2023, and net income of $8.0 million or $0.37 per diluted share, for the quarter ended September 30, 2022. Annualized return on average assets and return on average equity for the quarter ended September 30, 2023 was 1.10% and 10...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.